药明康德
(603259)
| 流通市值：1068.41亿 | | | 总市值：1230.83亿 |
| 流通股本：25.46亿 | | | 总股本：29.33亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 40,340,806,877.04 | 29,541,326,133.58 | 18,871,285,497.62 | 8,963,741,607.53 |
| 营业收入 | 40,340,806,877.04 | 29,541,326,133.58 | 18,871,285,497.62 | 8,963,741,607.53 |
| 二、营业总成本 | 28,708,590,806.38 | 20,390,754,912.94 | 13,155,192,160.22 | 6,775,228,643.47 |
| 营业成本 | 23,728,799,637.77 | 17,341,307,169.32 | 11,225,477,810.51 | 5,387,881,541.14 |
| 税金及附加 | 297,479,375.46 | 175,990,089.52 | 116,900,796.89 | 60,280,864.67 |
| 销售费用 | 701,029,692.54 | 521,220,394.83 | 353,474,082.14 | 175,853,794.43 |
| 管理费用 | 2,878,770,842.66 | 1,979,875,643.41 | 1,272,852,147.07 | 649,042,719.52 |
| 研发费用 | 1,440,630,437.19 | 1,025,811,070.87 | 667,045,046.51 | 357,301,004.44 |
| 财务费用 | -338,119,179.24 | -653,449,455.01 | -480,557,722.9 | 144,868,719.27 |
| 其中:利息费用 | 139,976,715.73 | 113,947,206.59 | 73,445,570.34 | 51,162,682.86 |
| 其中:利息收入 | 444,470,241.55 | 319,668,946.61 | 197,358,590.58 | 94,150,440.85 |
| 加:公允价值变动收益 | -37,809,127.95 | 102,676,079.72 | 310,992,128.5 | 164,608,536.39 |
| 加:投资收益 | 233,848,997.4 | 463,436,866.04 | 320,222,656.01 | 177,559,274.38 |
| 资产处置收益 | -33,450,046.48 | -5,697,972.07 | -3,673,282.4 | -1,778,767.47 |
| 资产减值损失(新) | -156,508,914.41 | -61,486,509.43 | -55,924,809.72 | -7,873,315.9 |
| 信用减值损失(新) | -238,403,367.77 | -128,620,014.23 | -101,271,634.68 | -7,361,222.94 |
| 其他收益 | 472,392,295.02 | 286,536,806.88 | 226,002,077.08 | 101,687,366.13 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 11,872,285,906.47 | 9,807,416,477.55 | 6,412,440,472.19 | 2,615,354,834.65 |
| 加:营业外收入 | 16,596,329.57 | 6,624,331.87 | 4,940,448.56 | 3,814,378.7 |
| 减:营业外支出 | 56,891,244.89 | 32,074,532.76 | 22,167,979.52 | 10,296,460.37 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 11,831,990,991.15 | 9,781,966,276.66 | 6,395,212,941.23 | 2,608,872,752.98 |
| 减:所得税费用 | 2,131,730,957.88 | 1,633,319,192.33 | 1,038,316,705.39 | 423,068,109.37 |
| 六、净利润 | 9,700,260,033.27 | 8,148,647,084.33 | 5,356,896,235.84 | 2,185,804,643.61 |
| 持续经营净利润 | 9,700,260,033.27 | 8,148,647,084.33 | 5,356,896,235.84 | 2,185,804,643.61 |
| 归属于母公司股东的净利润 | 9,606,749,135.07 | 8,076,407,160.91 | 5,313,119,704.09 | 2,168,128,379.15 |
| 少数股东损益 | 93,510,898.2 | 72,239,923.42 | 43,776,531.75 | 17,676,264.46 |
| (一)基本每股收益 | 3.27 | 2.75 | 1.81 | 0.74 |
| (二)稀释每股收益 | 3.24 | 2.73 | 1.79 | 0.72 |
| 八、其他综合收益 | 86,920,855.5 | -543,935,758.12 | -513,668,492.23 | -17,915,814.4 |
| 归属于母公司股东的其他综合收益 | 88,303,227.45 | -535,163,387.67 | -506,153,169.55 | -18,526,965.94 |
| 九、综合收益总额 | 9,787,180,888.77 | 7,604,711,326.21 | 4,843,227,743.61 | 2,167,888,829.21 |
| 归属于母公司股东的综合收益总额 | 9,695,052,362.52 | 7,541,243,773.24 | 4,806,966,534.54 | 2,149,601,413.21 |
| 归属于少数股东的综合收益总额 | 92,128,526.25 | 63,467,552.97 | 36,261,209.07 | 18,287,416 |
| 公告日期 | 2024-03-19 | 2023-10-31 | 2023-08-01 | 2023-04-25 |
| 审计意见(境内) | 标准无保留意见 | | | |